Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.74 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.74 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.74 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.74 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.74 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.71 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.69 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.69 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.69 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29995120 | 1.00 | P2RY1 (0.74) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL14853898 | 0.93 | P2RY1 (0.73) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL16203366 | 0.93 | P2RX3 (0.64) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL10295499 | 0.92 | P2RY1 (0.71) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL13995541 | 0.91 | DNPH1 (0.77) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL5365040 | 0.89 | P2RY1 (0.75) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL163281 | 0.89 | P2RY1 (0.75) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL1331755 | 0.89 | P2RY1 (0.75) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL1331745 | 0.89 | P2RY1 (0.75) | P2RY1P2RX3P2RX2P2RY2P2RX4 | |
| SCHEMBL29908846 | 0.89 | P2RY1 (0.75) | P2RY1P2RX3P2RX2P2RY2P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20090130154-A1 | Topical Delivery of Biological and Cosmetic Agents by Zeolites | BIODERM RESEARCH (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130154-A1 | Topical Delivery of Biological and Cosmetic Agents by Zeolites | TYR, MMP1, MMP17 | P2RY1 4719/4885P2RX3 4807/4885P2RX2 4648/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | P2RY1 825/4885P2RX3 1510/4885P2RX2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.